(Q40968204)

25 September 2017

1 reference

title

Tamoxifen: teaching an old drug new tricks? (English)

1 reference

25 September 2017

1 reference

Grainger DJ

1

1 reference

PubMed ID

8597938

25 September 2017

Metcalfe JC

series ordinal

2

1 reference

PubMed ID

8597938

25 September 2017

language of work or name

English

0 references

publication date

1 April 1996

1 reference

25 September 2017

1 reference

25 September 2017

2

1 reference

25 September 2017

4

1 reference

25 September 2017

381-385

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0496-381

25 September 2017

0 references

cites work

Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

Risk of endometrial cancer after tamoxifen treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Mammary tumor suppression by transforming growth factor beta 1 transgene expression

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

A pivotal role for TGF-beta in atherogenesis?

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Transcriptional interactions of transforming growth-factor-beta with pro-inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Targeting TGF-beta for treatment of disease

1 reference

https://api.crossref.org/works/10.1038%2FNM0496-381

7 January 2021

Identifiers

DOI

10.1038/NM0496-381

1 reference

25 September 2017

1 reference

PubMed ID

8597938